Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Background - The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTrials.gov, NCT02789332) investigated o...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2021
|
| In: |
Annals of oncology
Year: 2020, Jahrgang: 32, Heft: 1, Pages: 49-57 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2020.10.471 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2020.10.471 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753420429631 
|
| Verfasserangaben: | P.A. Fasching, T. Link, J. Hauke, F. Seither, C. Jackisch, P. Klare, S. Schmatloch, C. Hanusch, J. Huober, A. Stefek, S. Seiler, W.D. Schmitt, C. Uleer, G. Doering, K. Rhiem, A. Schneeweiss, K. Engels, C. Denkert, R.K. Schmutzler, E. Hahnen, M. Untch, N. Burchardi, J.-U. Blohmer & S. Loibl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1748264923 | ||
| 003 | DE-627 | ||
| 005 | 20240411193415.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210215r20212020xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2020.10.471 |2 doi | |
| 035 | |a (DE-627)1748264923 | ||
| 035 | |a (DE-599)KXP1748264923 | ||
| 035 | |a (OCoLC)1341393080 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fasching, Peter Andreas |d 1975- |e VerfasserIn |0 (DE-588)129068780 |0 (DE-627)388703040 |0 (DE-576)297477099 |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) |c P.A. Fasching, T. Link, J. Hauke, F. Seither, C. Jackisch, P. Klare, S. Schmatloch, C. Hanusch, J. Huober, A. Stefek, S. Seiler, W.D. Schmitt, C. Uleer, G. Doering, K. Rhiem, A. Schneeweiss, K. Engels, C. Denkert, R.K. Schmutzler, E. Hahnen, M. Untch, N. Burchardi, J.-U. Blohmer & S. Loibl |
| 264 | 1 | |c 2021 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online: 21 October 2020 | ||
| 500 | |a Gesehen am 15.02.2021 | ||
| 520 | |a Background - The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTrials.gov, NCT02789332) investigated olaparib in combination with paclitaxel in HER2-negative early BC with HRD. - Patients and methods - Patients with untreated primary HER2-negative cT2-cT4a-d or cT1c with either cN+ or pNSLN+ or cT1c and triple-negative breast cancer (TNBC) or cT1c and Ki-67>20% BC with HRD were randomised either to paclitaxel (P) 80 mg/m2 weekly plus olaparib (O) 100 mg twice daily for 12 weeks or P plus carboplatinum (Cb) area under the curve 2 weekly for 12 weeks, both followed by epirubicin/cyclophosphamide (EC). Stratification factors were hormone receptor (HR) status (HR+ versus HR−) and age (<40 versus ≥40 years). The primary endpoint was pathological complete response (pCR; ypT0/is ypN0). A two-sided one-group χ2-test was planned to exclude a pCR rate of ≤55% in the PO-EC arm. Secondary end points were other pCR definitions, breast conservation rate, clinical/imaging response, tolerability and safety. - Results - A total of 107 patients were randomised between September 2016 and July 2018; 106 (PO N = 69; PCb N = 37) started treatment. Median age was 47.0 years (range 25.0-71.0); 36.2% had cT1, 61.0% cT2, 2.9% cT3, and 31.8% cN-positive tumours; grade 3 tumours: 86.8%; Ki-67>20%: 89.6%; TNBC: 72.6%; confirmed gBRCA1/2 mutation: 56.2%. The pCR rate with PO was 55.1% [90% confidence interval (CI) 44.5% to 65.3%] versus PCb 48.6% (90% CI 34.3% to 63.2%). Analysis for the stratified subgroups showed higher pCR rates with PO in the cohorts of patients <40 years and HR+ patients. - Conclusion - GeparOLA could not exclude a pCR rate of ≤55% in the PO arm. PO was significantly better tolerated and the combination merits further evaluation. | ||
| 534 | |c 2020 | ||
| 650 | 4 | |a carboplatinum | |
| 650 | 4 | |a HER2-negative breast cancer | |
| 650 | 4 | |a HRD | |
| 650 | 4 | |a neoadjuvant therapy | |
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a PARP inhibitor | |
| 700 | 1 | |a Link, T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hauke, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seither, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jackisch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klare, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmatloch, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanusch, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Huober, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stefek, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Seiler, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmitt, W. D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uleer, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Doering, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rhiem, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schneeweiss, Andreas |d 1961- |e VerfasserIn |0 (DE-588)109972554 |0 (DE-627)632849630 |0 (DE-576)327251859 |4 aut | |
| 700 | 1 | |a Engels, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Denkert, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmutzler, R. K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hahnen, E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Untch, M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burchardi, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blohmer, J. -U. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loibl, S. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 32(2021), 1, Seite 49-57 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:1 |g pages:49-57 |g extent:9 |a Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2020.10.471 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753420429631 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210215 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 109972554 |a Schneeweiss, Andreas |m 109972554:Schneeweiss, Andreas |d 910000 |d 910400 |d 50000 |e 910000PS109972554 |e 910400PS109972554 |e 50000PS109972554 |k 0/910000/ |k 1/910000/910400/ |k 0/50000/ |p 16 | ||
| 999 | |a KXP-PPN1748264923 |e 385350633X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"recId":"320428796","id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"language":["eng"],"disp":"Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)Annals of oncology","physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"9","pages":"49-57","volume":"32","text":"32(2021), 1, Seite 49-57","issue":"1","year":"2021"},"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"origin":[{"dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","dateIssuedKey":"1990"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"pubHistory":["1.1990 -"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"name":{"displayForm":["P.A. Fasching, T. Link, J. Hauke, F. Seither, C. Jackisch, P. Klare, S. Schmatloch, C. Hanusch, J. Huober, A. Stefek, S. Seiler, W.D. Schmitt, C. Uleer, G. Doering, K. Rhiem, A. Schneeweiss, K. Engels, C. Denkert, R.K. Schmutzler, E. Hahnen, M. Untch, N. Burchardi, J.-U. Blohmer & S. Loibl"]},"recId":"1748264923","id":{"eki":["1748264923"],"doi":["10.1016/j.annonc.2020.10.471"]},"language":["eng"],"physDesc":[{"extent":"9 S."}],"origin":[{"dateIssuedDisp":"2021","dateIssuedKey":"2021"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","given":"Peter Andreas","family":"Fasching","display":"Fasching, Peter Andreas"},{"given":"T.","family":"Link","display":"Link, T.","role":"aut"},{"display":"Hauke, J.","given":"J.","family":"Hauke","role":"aut"},{"display":"Seither, F.","family":"Seither","given":"F.","role":"aut"},{"role":"aut","display":"Jackisch, C.","family":"Jackisch","given":"C."},{"display":"Klare, P.","family":"Klare","given":"P.","role":"aut"},{"display":"Schmatloch, S.","family":"Schmatloch","given":"S.","role":"aut"},{"display":"Hanusch, C.","given":"C.","family":"Hanusch","role":"aut"},{"display":"Huober, J.","family":"Huober","given":"J.","role":"aut"},{"role":"aut","display":"Stefek, A.","family":"Stefek","given":"A."},{"display":"Seiler, S.","given":"S.","family":"Seiler","role":"aut"},{"role":"aut","family":"Schmitt","given":"W. D.","display":"Schmitt, W. D."},{"role":"aut","display":"Uleer, C.","family":"Uleer","given":"C."},{"role":"aut","given":"G.","family":"Doering","display":"Doering, G."},{"role":"aut","family":"Rhiem","given":"K.","display":"Rhiem, K."},{"display":"Schneeweiss, Andreas","given":"Andreas","family":"Schneeweiss","role":"aut"},{"role":"aut","display":"Engels, K.","family":"Engels","given":"K."},{"display":"Denkert, C.","family":"Denkert","given":"C.","role":"aut"},{"role":"aut","family":"Schmutzler","given":"R. K.","display":"Schmutzler, R. K."},{"role":"aut","display":"Hahnen, E.","given":"E.","family":"Hahnen"},{"role":"aut","display":"Untch, M.","given":"M.","family":"Untch"},{"given":"N.","family":"Burchardi","display":"Burchardi, N.","role":"aut"},{"role":"aut","display":"Blohmer, J. -U.","given":"J. -U.","family":"Blohmer"},{"family":"Loibl","given":"S.","display":"Loibl, S.","role":"aut"}],"title":[{"title":"Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)","title_sort":"Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)"}],"note":["Available online: 21 October 2020","Gesehen am 15.02.2021"]} | ||
| SRT | |a FASCHINGPENEOADJUVAN2021 | ||